Top-Rated StocksTop-RatedNASDAQ:ASND Ascendis Pharma A/S (ASND) Stock Price, News & Analysis $194.30 +1.50 (+0.78%) Closing price 04:00 PM EasternExtended Trading$194.17 -0.13 (-0.07%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ascendis Pharma A/S Stock (NASDAQ:ASND) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ascendis Pharma A/S alerts:Sign Up Key Stats Today's Range$192.18▼$195.5550-Day Range$163.32▼$198.3252-Week Range$111.09▼$199.99Volume308,107 shsAverage Volume572,249 shsMarket Capitalization$11.89 billionP/E RatioN/ADividend YieldN/APrice Target$243.36Consensus RatingBuy Company Overview Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. Read More Ascendis Pharma A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreASND MarketRank™: Ascendis Pharma A/S scored higher than 67% of companies evaluated by MarketBeat, and ranked 353rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAscendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAscendis Pharma A/S has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ascendis Pharma A/S's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($4.34) to $0.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is -37.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is -37.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.52% of the float of Ascendis Pharma A/S has been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Ascendis Pharma A/S has recently increased by 1.10%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.52% of the float of Ascendis Pharma A/S has been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Ascendis Pharma A/S has recently increased by 1.10%, indicating that investor sentiment is decreasing. News and Social Media3.5 / 5News Sentiment1.21 News SentimentAscendis Pharma A/S has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Ascendis Pharma A/S this week, compared to 8 articles on an average week.Search InterestOnly 9 people have searched for ASND on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows4 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Ascendis Pharma A/S's insider trading history. Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ASND Stock News HeadlinesAscendis: After Long Bull Run, New Commercial Challenges Suggest Rating DowngradeAugust 21 at 10:48 AM | seekingalpha.comAscendis Pharma price target raised to $260 from $254 at JPMorganAugust 20 at 2:27 AM | msn.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 22 at 2:00 AM | Porter & Company (Ad)New Forecasts: Here's What Analysts Think The Future Holds For Ascendis Pharma A/S (NASDAQ:ASND)August 16, 2025 | finance.yahoo.comAscendis Pharma A/S Q2 Earnings Call Highlights GrowthAugust 13, 2025 | msn.comAscendis Pharma A/S (NASDAQ:ASND) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comAscendis Pharma A/S (NASDAQ:ASND) Hits New 12-Month High on Analyst UpgradeAugust 12, 2025 | americanbankingnews.comAscendis Pharma A/S (ASND) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | seekingalpha.comSee More Headlines ASND Stock Analysis - Frequently Asked Questions How have ASND shares performed this year? Ascendis Pharma A/S's stock was trading at $137.67 at the start of the year. Since then, ASND stock has increased by 41.1% and is now trading at $194.30. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) released its earnings results on Thursday, August, 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping analysts' consensus estimates of ($1.42) by $0.49. The biotechnology company earned $216.28 million during the quarter, compared to analyst estimates of $163.17 million. Read the conference call transcript. When did Ascendis Pharma A/S IPO? Ascendis Pharma A/S (ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager. Who are Ascendis Pharma A/S's major shareholders? Top institutional shareholders of Ascendis Pharma A/S include Westfield Capital Management Co. LP (8.91%), Artisan Partners Limited Partnership (6.53%), Massachusetts Financial Services Co. MA (3.11%) and Perceptive Advisors LLC (1.58%). How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD). Company Calendar Last Earnings8/07/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASND CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees1,017Year FoundedN/APrice Target and Rating Average Price Target for Ascendis Pharma A/S$243.36 High Price Target$307.00 Low Price Target$153.00 Potential Upside/Downside+25.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($5.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$409.12 million Net Margins-54.94% Pretax Margin-53.33% Return on EquityN/A Return on Assets-24.31% Debt Debt-to-Equity RatioN/A Current Ratio1.02 Quick Ratio0.69 Sales & Book Value Annual Sales$393.54 million Price / Sales30.22 Cash FlowN/A Price / Cash FlowN/A Book Value($3.48) per share Price / Book-55.83Miscellaneous Outstanding Shares61,210,000Free Float36,727,000Market Cap$11.89 billion OptionableOptionable Beta0.41 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ASND) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.